CERo Therapeutics Expands Intellectual Property with New Patents

CERo Therapeutics Enhances Its Intellectual Property Portfolio

CERo Therapeutics Holdings, Inc. (Nasdaq: CERO), an innovative immunotherapy company based in South San Francisco, has made significant strides in its mission to advance engineered T cell therapeutics. Recently, the company celebrated the granting of two U.S. patents and the allowance of a European patent application, marking a robust expansion of its intellectual property portfolio. This development is crucial as it strengthens the foundation for CERo's lead compound, CER-1236, aimed at treating various cancers.

Newly Granted Patents Supporting CER-1236

The U.S. Patent and Trademark Office (USPTO) has awarded CERo Patent No. 12,291,557, titled “Chimeric TIM4 Receptors and Uses Thereof.” This patent, granted on May 6, 2025, focuses on the innovative design components of CER-1236 and establishes valuable composition of matter protections for the chimeric TIM4 receptor.

European Patent Application Approval

Additionally, a European patent application has been allowed for Patent Application No. 1882166.7, titled “Chimeric Engulfment Receptor Molecules and Methods of Use.” This new development adds to the existing portfolio of protections for the innovative receptor design aspects of CER-1236, which have already seen success in the U.S., Japan, and China. Strengthening this platform is essential for CERo to maintain a competitive edge in the biotechnology space.

Combination Immunotherapy and Future Potential

In further developments, the USPTO also granted U.S. Patent No. 12,303,551 on May 20, 2025, covering various compositions and methods for combining cellular immunotherapy approaches. This patent protects the innovative combination of a chimeric engulfment receptor CD4+ T cell with other types of T cell therapies, paving the way for groundbreaking advancements in cancer treatment through combination therapies.

The strategic combination of CER-1236 with established therapies might create new avenues to combat cancer effectively. CERo's belief in the enhanced therapeutic potential of CER-T cells, which aim to harness both innate and adaptive immunity, could potentially transform current treatment paradigms.

Importance of Intellectual Property in Biotech

In the competitive realm of biotechnology, a strong intellectual property portfolio is vital. It provides essential protections that can enhance a company's market position and foster future innovations. Chris Ehrlich, CEO of CERo Therapeutics, emphasized the importance of these granted patents, noting that they serve as a pillar for the company's success, differentiating its CER-T technology from other therapies in the market.

Looking Ahead: Clinical Trials and Innovations

As the company moves forward, CERo anticipates updates related to its clinical trial milestones in acute myeloid leukemia (AML), alongside news of commencing human trials targeting ovarian and non-small cell lung cancers. These developments highlight CERo's commitment to advancing the field of immunotherapy and potentially providing new hope for cancer patients.

With these latest intellectual property advancements, CERo's portfolio now boasts a total of 18 issued patents and allowed patent applications globally. This achievement underscores the company's dedication to protecting its innovative technologies well into the future, with patent protections extending to 2042 in the United States, ensuring long-term viability and competitive positioning.

About CERo Therapeutics Holdings, Inc.

CERo Therapeutics is at the forefront of developing engineered T cell therapies tailored for cancer treatment. By integrating advantageous features from both innate and adaptive immunity into their therapeutic constructs, CERo aims to maximize the efficacy of cancer treatments. The proprietary CER-T technology, which utilizes chimeric engulfment receptors, focuses on enhancing the body’s immune response to annihilate tumors, aiming to surpass the performance of conventional CAR-T therapies across both hematological and solid tumors. As the first product candidate from CERo, CER-1236 is already undergoing clinical trials for hematological malignancies, representing a beacon of hope within the field.

Frequently Asked Questions

What are the newly granted patents for CERo Therapeutics?

CERo Therapeutics received two new U.S. patents and one European patent application allowance, expanding its intellectual property portfolio related to CER-1236.

What is the significance of CER-1236 for cancer treatment?

CER-1236 represents a groundbreaking engineered T cell therapy that employs phagocytic mechanisms to target and eliminate cancer cells, enhancing treatment efficacy.

How does CERo's intellectual property affect its market position?

A strong intellectual property portfolio reinforces CERo's market position by protecting its innovative technologies, ensuring a competitive edge in the biotechnology sector.

What are CERo's upcoming clinical trial plans?

CERo plans to update stakeholders on clinical trial progress in AML and intends to initiate human trials for treatments targeting ovarian and non-small cell lung cancers.

What makes CER-T technology different from conventional therapies?

CER-T technology combines characteristics of both innate and adaptive immunity, allowing for more effective responses against a broader range of cancers compared to traditional CAR-T therapies.

About The Author

Greetings, I'm 32-year-old author and financial specialist Evelyn Baker. My introduction into the financial industry started with an economics degree and continued with a wealth of experience in wealth management and financial consulting. My great passion over the years has been assisting people and companies in making wise, well-informed decisions to reach their financial objectives.

My goal with writing is to simplify difficult financial ideas into understandable, doable guidance. My goal in writing many books and articles is to make personal finance understandable to everyone, irrespective of their experience or background. I want to give readers the information they need to take charge of their financial futures, from investing and retirement planning to budgeting and saving.

Along with my writing, I lead webinars and workshops where I provide doable advice and methods for achieving financial success. To reach a larger audience, I also frequently contribute to financial blogs and publications. My method is always to offer doable, real-world guidance that can actually improve people's lives.

Aside from my job, I like to cook, travel, and experience other cultures. I work hard to apply my belief in the value of a balanced life to my financial counsel. My goal in working is to encourage and enable people to succeed financially so they may lead the best lives possible.

Contact Evelyn Baker privately here. Or send an email with ATTN: Evelyn Baker as the subject to contact@investorshangout.com.

About Investors Hangout

Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/

The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.